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Abstract: 
Antipsychotic medication is effective in reducing psychotic symptoms but use is associated 
with weight gain. Weight gain is associated with an increased risk of a number of life 
threatening health conditions. Multi-component lifestyle interventions are the recom-
mended non-pharmacological way of tacking weight gain and its consequences. This re-
view summarises the evidence for the effectiveness of multi-component lifestyle interven-
tion in reducing weight and waist circumference in adults taking antipsychotics. The review 
of eight studies found that such approaches are effective, however multiple factors affect 
success, for example tailoring of information to the cognitive abilities of participants and 
the use of individual combined with group approaches. Eight studies were reviewed. There 
were some unexpected results within studies, where some control groups lost weight or 
decreased waist circumference as well as intervention groups. Reasons for significant 
weight change in control groups was attributed to possible access to weight loss activities 
outside of the intervention programmes. Adherence to intervention programmes was also 
important for success. Nurses who support antipsychotic users to lose weight should pro-
mote multi-component approaches that are tailored to the specific needs of this group.  
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• Weight gain is a major concern for people prescribed antipsychotics, affecting treatment 
adherence and heightening risk of a number of life threatening physical health condi-
tions.  
• Multi-component lifestyle interventions, comprising diet and exercise educational and be-
havioural interventions are the nationally recommended first line approach to weight 
gain.  
• There have been a number of randomised control trial (RCT) studies of multi-component 
lifestyle interventions for people taking antipsychotics.  
• Successful weight loss is possible if interventions contain both group and individual ele-
ments and if the content is tailored to this specific population.  
• More research is needed to compare effectiveness of multi-component interventions be-
tween populations taking antipsychotics, namely people with different degrees of obesity, 
levels of cognitive functioning and ethnicity.  
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Introduction 
Antipsychotic medications are effective for the treatment and management of psychotic 
symptoms; however they often produce unpleasant side effects (Lally & MacCabe 2015). 
One of these includes weight gain (Bak et al, 2014). The mechanisms of antipsychotic re-
lated weight gain are thought to be associated with their effect on histamine, serotonin and 
acetylcholine metabolism (Richards & Bressington 2015). Adults taking antipsychotics long 
term have a reduced life expectancy due to the increased prevalence of obesity (Olfson et 
al, 2015), with a study by Chang et al, (2011) finding that men with schizophrenia’s life ex-
pectancy was reduced by 14.6 years and women with schizoaffective disorders reduced 
by 17.5 years. Antipsychotic weight gain costs the healthcare system as well as the indi-
vidual (Shrivastava & Johnston 2010). Experiencing weight gain can often lead to adults 
deciding to stop compliance with antipsychotic regimes (Eapen & John 2011). Antipsychot-
ic regime non-adherence increases the frequency and duration of hospital admissions, 
and use of secondary care services (Marcus & Olfson (2008) and this can have a signifi-
cant impact on health and wellbeing. Rege (2008) states that achieving an optimal balance 
between effectiveness and weight maintenance in antipsychotic treatment is possible if 
appropriate intervention occurs. Obesity in this population is usually a result of lifestyle fac-
tors such as inactivity or poor diet (Gossage-Worrall et al. 2016), hence, this is a crucial 
area to target. 
 
The consequences of obesity: metabolic syndrome, diabetes and cardiovascular disease 
can be reduced if weight is lost (Heald 2010). Pharmacological interventions are often 
used for weight loss, such as switching antipsychotics or the use of metformin (Shrivasta-
va & Johnston 2010, Mizuno et al, 2014), however, non-pharmacological interventions 
may be more appealing to service users as there is not the same risk of further medication 
side effects (Caemmerer et al, 2012).  A lifestyle-focused, health promotion approach to 
Anonymous manuscript Click here to download Anonymous manuscript DA BJMHN
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physical wellbeing has been advocated within mental health services for several years alt-
hough gaps in the provision of high quality physical healthcare for people with severe 
mental illness remain (McGuinness & Folan, 2016).  
Multi-components lifestyle interventions are non-pharmacological interventions that are 
usually administered between 3-18 months (McCloughen & Foster 2011) composed of two 
or more elements such as diet modification and increased physical activity (McCloughen & 
Foster 2011). Previous systematic reviews have found that such approaches support 
weight loss in adult populations (Poobalan et al, 2009, Mitchell et al, 2014, Hassan et al, 
2016). Recent reviews have found that multi-component interventions can reduce weight 
with serious mental illness (Olker et al, 2016, Naslund et al, 2017). The National Institute 
of Health and Clinical Excellence (NICE) guidelines on psychosis (2014a) advocate multi-
component lifestyle interventions for excessive weight gain (NICE 2014b; 2015). However, 
a limited number of reviews have explored the effectiveness, specifically focusing on com-
paring service users who use antipsychotics (Olker et al, 2017, Bushe et al, 2009; Murray 
et al, 2017) and aiming to inform mental health nursing practice.  
 
Aim  
The aim of this review is to explore the success of multi-component lifestyle interventions 
in reducing obesity in adult populations on antipsychotics, focusing on weight, BMI and 
waist circumference as primary outcomes. 
 
Methods 
A search was undertaken using the following databases; Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), Medline, Web of Science and PsycInfo. Search terms 
were derived using a PICO approach (Population, Intervention, Comparator and Out-
come): multi-component lifestyle interventions (Intervention) for supporting weight loss 
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(Outcome) in adults on antipsychotic medication (Population) in comparison to non-
intervention (Comparator). The search process is shown in a PRISMA flow diagram 
(Moher et al, 2009) in Figure 1. The inclusion criteria for the studies were: published in 
English language with adults (18 years and above) who were currently on antipsychotic 
medication. Only randomised-controlled trials (RCTs) were included. The included study 
papers were reviewed in full and summarised using a data extraction form. Study quality 
was assessed using the Critical Appraisal Skills Programme (CASP; 2013) checklist for 
RCTs. Additionally, the Cochrane Handbook risk of bias tool (Higgins & Green 2011) was 
used to assess of bias and study validity.   
 
Results 
8 papers were included, describing 8 RCT studies. Table 1 provides a summary of study 
characteristics. 55.7% of the participants were female and 44.3% were male. The mean 
ages within studies ranged from 26.3 to 48.8 years. Intervention and control groups char-
acteristics were similar at the start of the trials aside from Ratliff et al, (2012) where the 
baseline antipsychotic dose was statistically different between the groups. Selection crite-
ria for study participants were that they had to be taking antipsychotics and had experi-
enced weight gain. Doses for specific drugs or duration of their use were not reported, 
apart from in Wu et al, (2007) where all participants had been on at least 300mg clozapine 
for over a year. Attux et al, (2013) listed the numbers of participants on different antipsy-
chotics but found no difference in results between those on first generation or second 
generation drugs.  
Interventions 
Interventions ranged from 2 and 12 months in duration and the mean intervention duration 
was 4 months. Wu et al, (2007) was the only study in which diet was fully controlled as 
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their participants were inpatients. All other studies took place in the community. Six studies 
provided exercise sessions (Wu et al, 2007, Wu et al, 2008, Usher et al, 2012, Green et al, 
2014, Masa-Font et al, 2015, Green et al, 2015). Two studies did not provide exercise 
sessions but encouraged physical activity through psychoeducation (Attux et al, 2013) or a 
combination of psychoeducation and Contingency Management (CM), which is a behav-
ioural technique whereby participants are offered financial incentives for either buying 
healthy food, losing weight or attending the programme (Ratliff et al, 2013).  
Five studies tailored their intervention for the specific population. Usher et al, (2012) 
adapted their intervention to account for the cognitive complications that can occur with a 
diagnosis of schizophrenia, for example, differing levels of literacy, difficulty in conversa-
tion and impaired memory. They also added visual representations of the training sessions 
to aid learning. Green et al, (2014) equally adapted their intervention to meet the cognitive 
needs of participants, adjusting the pace and breaking down information and tasks. Green 
et al, (2015) did the same and additionally provided psychoeducation around the effects of 
antipsychotics. Ratliff et al, (2012) used a lifestyle intervention that was specifically created 
for individuals with mental illness. It assumed no knowledge of the discussed topics and 
used simplified terms. The programme that Attux et al, (2013) used was developed for in-
dividuals on antipsychotics and included a session to support motivation and self-esteem. 
Adapting the intervention ensures it is as appropriate for the population as possible.  
Intervention adherence 
Data on treatment adherence is crucial as this provides us with information on intervention 
acceptance by participants (Zhang et al, 2014). Attrition can create bias within a study, if 
results favour participants who stay, leading to underestimation about the potential compli-
cations of the intervention (Peterson et al, 2012). Only one study had 100% adher-
ence/attendance within their intervention. This was Wu et al, (2007) and was likely to be 
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achieved because the intervention was carried out within an inpatient environment. Fur-
thermore, studies that include social support have higher intervention adherence rates 
(Lemstra et al, 2016). This was true within the studies by Attux et al, (2013) and Green et 
al, (2014), who invited families to come to intervention group sessions. Similarly, the study 
by Wu et al, (2007) required carers to support the physical activity component and inter-
vention adherence was relatively high (55-74%). There is no specified point at which inter-
vention attrition becomes an issue, but rather bias is introduced if there are differences in 
participants who left the intervention and the control group (Dumville et al, 2006).  Ratliff et 
al, (2012) stated that one participant dropped out from each condition; however, there was 
no explanation for this. Usher et al, (2012) reported that two participants left due to medi-
cal reasons, but did not state what these were and what group they were randomised to. 
Although Attux et al, (2013) provided detail on most drop-outs; there were a total of 8 par-
ticipants where reasons for dropping out were unknown. Within these studies, there is an 
unclear risk of attrition bias. In the study by Masa-Font et al, (2015) information on attrition 
was provided; however, there was a death in the intervention group and details of this was 
not provided. Masa-Font et al, (2015) had the lowest intervention adherence; this was be-
tween 42.6-58%. This was the only study where the intervention group gained weight. A 
recent meta-analysis of weight loss intervention studies across all populations by Lemstra 
et al, (2016) explains this pattern simply: if participants do not adhere to the weight loss 
interventions then they will not lose weight, and may even gain it.  
Weight loss 
Figure 2 shows the changes in weight (kg) within the intervention and control 
groups. The intervention group with the greatest statistical significant weight loss was 
Green et al, (2015) after the initial intervention phase (4.2354 kg). Although weight loss 
after the maintenance phase was larger (4.887 kg) it was not significantly different 
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(95%CI). This result suggests that the intensity and greater number of sessions may be a 
key component of success within these interventions. Attux et al, (2013) found that signifi-
cant weight loss (1.15 kg) occurred at their last measurement of 3 months’ post interven-
tion but not immediately at intervention end where weight loss was insignificant (0.4 
kg)(p<0.05). This highlights that the effects of lifestyle interventions may not be immediate, 
emphasizing the need for post-intervention measurements, to see how outcomes develop 
over a longer period. Participants in the intervention by Wu et al, (2007) lost a mean of 1.3 
kg, suggesting that even a program simply consisting of calorie constriction and walking 
may support weight loss in an inpatient environment (p<0.05). In the study by Ratliff et al, 
(2012) only weight loss in the intervention group receiving financial incentives for choosing 
healthy food was significant (2.54 kg)(p<0.02). The other two intervention groups (reward-
ing for attendance or weight loss) lost weight but not significantly when compared to con-
trols. This suggests that lifestyle interventions combined with CM rewarding for behaviour 
change may be the most effective in this population. The nurse-led intervention by Usher 
et al, (2012) produced the least weight loss (0.74 kg) and was not statistically significant 
(p<0.05). Usher et al, (2012) provided control participants with a copy of the intervention 
education booklet, and here the control group weight also decreased. This suggests that 
even minimal intervention such as educational booklets may influence behaviour change 
and weight loss. The control group in the study by Green et al, (2014) lost 0.3kg but this 
was not explained. However, in Green et al, (2014) this did not change their BMI. Green et 
al, (2015) found that the intervention group lost 2.6 kg more than the control group after 
the maintenance phase. However, there was no significant difference in weight change 
between the groups (95% CI). This was attributed to the opportunity control group partici-
pants had to engage in other weight-loss methods. Nonetheless, at the end of the initial 
intervention the control group had an increase in weight (0.96 kg).  
multi-component review 
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Only one study (Attux et al, 2013) presented information about how long weight loss was 
maintained post- intervention. They found that weight loss was not significant immediately 
post-intervention but 3 months’ post-intervention it was significant. The study by Green et 
al, (2015) was followed up in a separate study. In contrast, at one-year post-intervention, 
weight change between intervention and control group participants was statistically insig-
nificant (Green et al, 2016). This suggests that whilst multi-component interventions have 
the potential to be beneficial to the health of an adult on antipsychotic medication; it is still 
unclear how long these positive effects last.  
BMI  
Figure 3 shows the BMI changes (kg/m2) within the intervention and control groups. 
All studies within the review measured BMI. However, three studies (Ratliff et al, 2012; 
Green et al, 2014; Green et al, 2015) did not report BMI results for all conditions so have 
not been included in the comparison chart. Six studies found a statistical difference be-
tween the intervention and control groups for BMI. In all the studies but Usher et al, (2012) 
and Masa-Font et al, (2015) the BMI of the intervention group decreased yet increased 
within the control group. Usher et al, (2012) found that BMI decreased in both the interven-
tion (0.25 kg/m2) and control (0.06 kg/ m2) group. As stated above, this difference was not 
statistically significant (p>0.05). The study by Masa-Font et al, (2015) was the only one 
where the intervention group gained weight and the control group lost weight. They found 
that the control group’s BMI decreased significantly (0.23kg/m2) in comparison to the in-
tervention group where BMI increased on average (0.04kg/m2) (p<0.05). They attributed 
this result to the fact that that control group participants may have engaged in other weight 
loss programmes and the low adherence rates within the intervention group. 
Waist circumference 
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Waist circumference measurements are effective long term measures of weight loss 
maintenance post-interventions (Millstein 2014). Six studies measured waist circumfer-
ence. Comparisons between intervention and control groups are presented in Figure 
4. Wu et al, (2007) and Wu et al, (2008) were the only studies to find statistical significance 
in waist circumference between the intervention and control groups (p<0.05). In three stud-
ies waist circumference, decreased in the intervention group and increased in the control 
group (Wu et al, 2007, Ratliff et al, 2012, Attux et al, 2013). However, in the studies by Wu 
et al, (2008), Usher et al, (2012) and Masa-Font et al, (2015) this was not the case. Wu et 
al, (2008) reported an increase in waist circumference in both the intervention (0.1 cm) and 
control (2.2 cm) groups. Usher et al, (2012) found a waist circumference decrease in both 
the intervention group (1.23 cm) and control group (0.15 cm). Masa-Font et al, (2015) 
found that the control group’s waist circumference decreased (0.018 cm) and the interven-
tion group waist circumference increased (0.98 cm).  
In addition to waist circumference Wu et al, (2007) measured body fat percentage, hip cir-
cumference and waist-to-hip ratio. They found a statistical difference in hip circumference 
between the intervention (3.3 cm) and control group (0.3 cm) at the intervention end 
(p<0.05). For waist-to-hip ratio they did not find a significant difference between the inter-
vention (0.1) and control group (0.1). Similarly, they found that body fat percentage was 
not significantly lower within or between the intervention (1.3%) and control (1.3%) groups. 
Nevertheless, these parameters decreased with intervention and increased with non-
intervention.  
Risk of bias 
A summary review of risk of bias is shown in Table 2. According to the Cochrane criteria 
(Higgins & Green 2011), all the studies included in this review had a risk of performance 
bias because the nature of the intervention was not concealable. Additionally, methods of 
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randomisation were not stated in two studies (Wu et al, 2007; Usher et al, 2012). Alloca-
tion concealment information was not reported in three studies (Wu et al, 2007; Ratliff et 
al, 2012; Attux et al, 2013) so risk of selection bias was unclear. One study did not provide 
the data of all outcomes for the insignificant results (CM-weight and CM-attendance) 
whereas they did for the significant results (CM-behaviour) (Ratliff et al, 2012).  
Discussion 
This review has expanded upon the findings of previous reviews, which made the case for 
further investigation into similar interventions (Caemmerer et al, 2012, Bruins et al, 2014). 
We have included additional RCTs, exploring a wider range of interventions, focusing sole-
ly on weight change and updating the current evidence. Our findings are consistent with 
those of existing reviews regarding various non-pharmacological interventions on individu-
als on antipsychotics which found that intervention was successful for both weight loss 
and/or weight-gain prevention in comparison to control groups (Bonfoli et al, 2012, 
Caemmerer et al, 2012, Bruins et al, 2014). Our review has considered more anthropomet-
ric measures than previous reviews, to explore weight loss in greater depth. 
Overall, when compared to a control group, adults taking antipsychotics lose weight when 
enrolled on multi-component lifestyle interventions. Combined mean weight change across 
the interventions was -2.72 kg (excluding those who didn’t provide baseline weight in kg). 
This corresponded to a weight loss of 2.93% from baseline. Although weight loss is usually 
reported as at least 5% to be considered clinically significant (Lagerros & Rossner 2013), 
even small decreases in weight can induce corresponding reductions in physical health 
complications and early mortality (Alvarez-Jimenez et al, 2008, Bruins et al, 2014).  
Current clinical guidelines on weight management (NICE 2014a) and schizophrenia (NICE 
2015) encourage the use of multi-component interventions to support weight loss although 
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there is no specific guidance for interventions for antipsychotic weight gain. The evidence 
from this review suggests that interventions should be tailored, suggesting the benefit of 
an additional clinical guidance specifically for adults on antipsychotic medication. For ex- 
ample, a diagnosis of schizophrenia may mean that levels of concentration and compre- 
hension abilities that need to be accounted for through intervention adaptations (Usher et 
al, 2012).  
There is a lack of information in included studies about how long weight loss is maintained 
post-intervention, as only Attux et al, (2013) provided this information, finding that interven-
tion end weight loss was not significant, but 3 months’ post-intervention, weight loss was 
significant. The study by Green et al, (2015) was followed up in a separate study. In con-
trast, at one-year post-intervention, weight gain between intervention and control group 
participants was statistically insignificant (Green et al, 2016). This suggest that furth work 
must be done to track weight change and maintenance post-intervention. Masa-Font et al 
(2015) had the lowest intervention adherence of between 42.6 and 58%. Theirs was the 
only study where the intervention group gained weight. The recent meta-analysis by Lem-
stra et al, (2016) offers an explanation for this. They state that if participants do not adhere 
with weight loss interventions then they will not lose weight, and may even gain it. Inter-
ventions with family/social support had higher adherence rates. Hence, the involvement of 
family and carers may further encourage and provide motivation for participants to engage.  
Studies characterised by a mixture of both an individual and group approach were more 
effective than studies that used only one of these components. Individual approaches al-
low for personal advice and specific goals to be created. Group approaches usually pro-
vide an element of social support and shared learning. .  A combined approach provides a 
space where the benefits of both can be gained. Additionally, it appears that success can 
occur in both inpatient and outpatient settings. However, as only one study was conducted 
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in an inpatient setting, it would be premature to generalise these results to all inpatient en-
vironments. 
Limitations 
This review has limitations. It has focused on three primary outcomes: weight loss, waist 
circumference reduction and BMI reduction. More detail on the differences within the popu-
lation taking antipsychotics should be accounted for, for example variation in doses of an-
tipsychotics and brand of antipsychotics used and differentiation between age and dura-
tion of antipsychotic use between participants. Measuring the differing effects of these in-
terventions with people with different degrees of being overweight and obesity, on different 
antipsychotics and of different ethnicities was not possible given current study information. 
Also, the multicomponent interventions reported here varied in duration and content. 
Whilst it is possible to summarise that such interventions work, there must be more analy-
sis of the aspects of such interventions that are effective, and comparison between types 
of intervention. Additionally, as all studies included within this review were RCTs, the re-
sults may not be as representative of the naturalistic environment. It may be beneficial to 
include a qualitative element in future studies, in order to gain service users’ insights into 
what worked and why.  The intervention and data collection periods ranged from 3 to 12 
months so future studies would benefit from measuring sustained weight loss over longer 
periods of time. 
Conclusion 
This review found that weight loss, BMI reduction and decreased waist circumference in 
adults taking antipsychotics is possible if multi-component interventions are adhered to. If 
multi-component lifestyle interventions provide tailored support then they have more po-
tential to produce clinically significant weight loss. Further research is needed to explore 
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booster/maintenance interventions, monitor long term effects, intervention cost-
effectiveness and compare the use of both tailored and longer interventions. 
Practice Implications 
For the included studies, limited weight loss within intervention groups was attributed to 
several factors: particularly lack of intervention adherence and use of interventions that 
were not tailored to the client’s needs. It is crucial that all nurses are aware of the im-
portance of offering antipsychotic users interventions that are appropriate for their treat-
ment regimes and cognitive abilities. Nurses should ensure that they are supporting anti-
psychotic users to attend sessions. In a population where treatment adherence is an 
acknowledged concern, close attention should be paid to what motivates individuals on 
antipsychotics to commit or drop out of such treatment programmes.  
 
3430 words 
References 
Alvarez-Jimenez M., Hetrick S., Gonzalez-Blanch C., Gleeson J. & McGorry P. (2008) 
Non-pharmacological management of antipsychotic-induced weight gain: systematic re-
view and meta-analysis of randomised controlled trials. The British Journal of Psychiatry 
193(2), 101-107.  
Attux C., Martini L., Roma C., Bressan A. & Mullan E. (2008) Non pharmacological man-
agement of weight gain: a national, multi centric study for schizophrenia and severe men-
tal disorders. Schizophrenia Research Amsterdam 98(52).  
multi-component review 
13 
13 of 19 
Attux C., Martini L.C., Elkis H., Tamai S., Freirias A., Camargo M., Mari J., Reis A. & Bres-
san R. (2013) A 6-month randomised controlled trial to test the efficacy of a lifestyle inter-
vention for weight gain management in schizophrenia. BMC Psychiatry 13(60).  
Bak M., Drukker M., van Os J., Janssen J. & Fransen, A. (2014) Almost all Antipsychotics 
result in weight gain: A Meta-Analysis. Public Library of Science 9(4): e94112. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998960/  
Ben Richards, D. & Bressington, D (2015) Understanding antipsychotic- induced weight 
gain and other metabolic issues. British Journal of Metal Health Nursing. July/August 2015 
4:4,  157-166 
Bruins J., Jorg F., Bruggeman R., Slooff C., Corpeleijn E. & Pijnenborg M. (2014) The Ef-
fects of Lifestyle Interventions on (Long-Term) Weight Management, Cardiometabolic Risk 
and Depressive Symptoms in People with Psychotic Disorders: A Meta-Analysis. PLoS 
ONE 9(12): e112276. https:// 
www.ncbi.nlm.nih.gov/pmc/articles/PMC4256304/pdf/pone.0112276.pdf  
Bushe C., Karagianis J., Doshi S. & Bradley A. (2009) Changes in weight and metabolic 
parameters during treatment with antipsychotics and metformin: Do the data inform as to 
potential guideline development? A systematic review of clinical studies. International 
Journal of Clinical Practice 63(12), 1743-1761.  
Caemmerer J., Maayan L. & Correl C. (2012) Acute and maintenance effects of non-
pharmacologic interventions for antipsychotic associated weight gain and metabolic ab-
normalities: A meta-analytic comparison of randomized controlled trials. Schizophrenia 
Research 140(1–3), 159–168.  
Chang, C. K., Hayes, R. D., Perera, G., Broadbent, M. T., Fernandes, A. C., Lee, W. E., ... 
& Stewart, R. (2011). Life expectancy at birth for people with serious mental illness and 
multi-component review 
14 
14 of 19 
other major disorders from a secondary mental health care case register in London. PloS 
one, 6(5), e19590. 
Cooper S. & Reynolds G. (2016) BAP guidelines on the management of weight gain, met-
abolic disturbances and cardiovascular risk associated with psychosis and antipsychotic 
drug treatment. Journal of Psychopharmacology 30(8), 717-748.  
Critical Appraisal Skills Programme (2013) Critical appraisal skills Programme (CASP) 
checklists. Retrieved from http://www.casp-uk.net/casp-tools-checklists on 1 January 
2017.  
De Hert M., Correll C., Yu W., van Winkel R. & Detraux J. (2012) Metabolic and cardiovas-
cular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 
8(2), 114-126.  
Dumville J., Torgerson D. & Hewitt C. (2006) Reporting attrition in randomised controlled 
trials. British Medical Journal 332(7547), 969-971.  
Eapen, V., & John, G. (2011). Weight gain and metabolic syndrome among young patients 
on antipsychotic medication: what do we know and where do we go?. Australasian Psy-
chiatry, 19(3), 232-235. 
Garcia-Ruiz A.J., Pérez-Costillas L., Montesinos A.C., Alcalde J., Oyagüez I. & Casado 
M.A. (2012) Cost-effectiveness analysis of antipsychotics in reducing schizophrenia re-
lapses. Health Economics Review 2(8).  
Gossage-Worrall R., Holt R., Barnard K., Carey M., Davies M., Dickens C., Doherty Y., 
Edwardson C., French P., Gaughran F., Greenwood K., Kalidindi S., Hind D., Khunti K., 
McCrone P., Mitchell J., Pendlebury J., Rathod S., Shiers D., Siddiqi N., Swaby L. & 
multi-component review 
15 
15 of 19 
Wright S. (2016) STEPWISE – STructured lifestyle Education for People WIth Schizo-
phrEnia: a study protocol for a randomised controlled trial. Trials 17(475), 1-12. 
Green C., Janoff S., Yarborough B. & Yarborough M. (2014) A 12-Week Weight Reduction 
Intervention for Overweight Individuals Taking Antipsychotic Medications. Community 
Mental Health Journal 50(8), 974-980.  
Green C., Yarborough B., Leo M., Yarborough M., Stumbo S., Janoff S., Perrin N., Nichols 
G. & Stevens V. (2015) The STRIDE Weight Loss and Lifestyle Intervention for Individuals 
taking Antipsychotic Medications: A Randomized Trial. The American Journal of Psychiatry 
172(1), 71-81.  
Green C., Yarborough B., Leo M., Stumbo S., Perrin N., Nichols G. & Stevens V. (2016) 
Weight Maintenance Following the STRIDE Weight Loss and Lifestyle Intervention for In-
dividuals taking Antipsychotic Medications. Obesity (Silver Spring) 23(10), 1995–2001.  
Hassan Y., Ford J., Diu S., Bachmann M., Jacob D. & Head V. (2016) Lifestyle interven-
tions for weight loss in adults with severe obesity: A systematic review. Clinical Obesity 
6(6), 395-403.  
Heald A. (2010) Physical health in schizophrenia: A challenge for antipsychotic therapy. 
European Psychiatry: The journal of the Association of European Psychiatrists 25(2), 6-11.  
Higgins J. & Green S. (eds) (2011) Cochrane handbook for systematic reviews of interven-
tions. Version 5.1.0 Retrieved from http://handbook.cochrane.org on 31 December 2016.  
Lagerros Y. & Rossner S. (2013) Obesity management: what brings success? Therapeutic 
Advances in Gastroenterology 6(1), 77-88.  
Lally J. & MacCabe J.H. (2015) Antipsychotic medication in schizophrenia: a review. Brit-
ish Medical Bulletin 114(1), 169-179.  
multi-component review 
16 
16 of 19 
Laursen T., Vestergaard M. & Munk-Olsen T. (2012) Life expectancy and cardiovascular 
mortality in persons with schizophrenia. Current opinion in psychiatry 25(2), 83-88.  
Lemstra M., Rogers M., Bird Y., Nwankwo C. & Moraros J. (2016) Weight-loss intervention 
adherence and factors promoting adherence: a meta-analysis. Patient Preference and Ad-
herence 12(10), 1547-1559.  
Marcus S. & Olfson M. (2007) Outpatient Antipsychotic treatment and inpatient costs of 
schizophrenia. Schizophrenia Bulletin 34(1), 173-180.  
Masa-Font R., Fernández-San-Martín M.I., Martín-López L.M., Alba-Muñoz A.M., Oller-
Canet S., Martín-Royo J., San Emeterio Echevarría L., Olona-Tabueña N., Ibarra-Jato M., 
Barroso-García A., González-Tejón S., Tajada-Vitales C., Díaz- Mújica B., Viñas-Cabrera 
L., Sanchís-Catalán R. & Salvador-Barbarroja T. (2015) The effectiveness of a program of 
physical activity and diet to modify cardiovascular risk factors in patients with severe men-
tal illness after 3-month follow-up: CAPiCOR randomized clinical trial. European Psychiatry 
30(8), 1028-1036.  
McCloughen A. & Foster K. (2011) Weight gain associated with taking psychotropic medi-
cation: An integrative review. International Journal of Mental Health Nursing 20(3), 202-
222.  
McGuinness & Folan (2016) severe mental illness and physical healthcare.  British Journal 
of Mental Health Nursing March/April 2016 5: 2, 81-86 
Millstein R.A. (2014) Measuring Outcomes in Adult Weight Loss Studies That Include Diet 
and Physical Activity: A Systematic Review. Journal of Nutrition and Metabolism 2014. 
doi:10.1155/2014/421423  
multi-component review 
17 
17 of 19 
Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W. & De Hert M. (2011) Prev-
alence of metabolic syndrome and metabolic abnormalities in schizophrenia and related 
Disorders—A systematic review and Meta-Analysis. Schizophrenia Bulletin 39(2), 306-
318.  
Mitchell L., Truby H., Hamilton G., O'Driscoll D., Bonham M. & Davidson Z. (2014) Weight 
loss from lifestyle interventions and severity of sleep apnoea: A systematic review and me-
ta-analysis. Sleep medicine 15(10), 1173-1183.  
Mizuno Y., Uchida H., Wolfgang W., Mimura M., Yoshida K., Nakagawa A. & Suzuki T. 
(2014) Pharmacological strategies to counteract Antipsychotic-Induced weight gain and 
metabolic adverse effects in schizophrenia: A systematic review and Meta-analysis. 
Schizophrenia Bulletin 40(6), 1385-1403.  
Moher D., Altman D., Tetzlaff J. & Liberati A. (2009) Preferred reporting items for system-
atic reviews and Meta-Analyses: The PRISMA statement. PLoS Medicine 6(7), 1-6.  
Murray R., Correll C., Reynolds G. & Taylor D. (2017) Atypical antipsychotics: recent re-
search findings and applications to clinical practice: Proceedings of a symposium present-
ed at the 29th Annual European College of Neuropsychopharmacology Congress, 19 Sep-
tember 2016, Vienna, Austria. Therapeutic Advances in Psychopharmacology 7(1), 1-14.  
Naslund, J. A., Aschbrenner, K. A., Kim, S. J., McHugo, G. J., Unützer, J., Bartels, S. J., & 
Marsch, L. A. (2017). Health behavior models for informing digital technology interventions 
for individuals with mental illness. Psychiatric Rehabilitation Journal, 40(3), 325. 
NICE (2014a) Psychosis and schizophrenia in adults: Prevention and management. Re-
trieved from https://www.nice.org.uk/guidance/cg178/chapter/1- recommendations#care-
across-all-phases on 25 December 2016.  
multi-component review 
18 
18 of 19 
NICE (2014b) Weight management: Lifestyle services for overweight or obese adults. Re-
trieved from https://www.nice.org.uk/guidance/ph53 on 3 November 2016.  
NICE (2015) Obesity prevention. Retrieved from https://www.nice.org.uk/guidance/ cg43 
on 3 November 2016.  
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality 
among adults with schizophrenia in the United States. JAMA psychiatry, 72(12), 1172-
1181. 
Olker, S. J., Parrott, J. S., Swarbrick, M. A., & Spagnolo, A. B. (2016). Weight manage-
ment interventions in adults with a serious mental illness: A meta-analytic review. Ameri-
can Journal of Psychiatric Rehabilitation, 19(4), 370-393. 
Peterson J., Pirraglia P., Wells M. & Charlson, M. (2012) Attrition in longitudinal random-
ized controlled trials: home visits make a difference. BMC Medical Research Methodology 
12(1), 78.  
Poobalan A., Smith W., Crombie I., Precious E. & Aucott L. (2009) Weight loss interven-
tions in young people (18 to 25 year olds): A systematic review. Obesity Reviews 11(8), 
580-592.  
Ratliff J.C., Palmese L.B., Tonizzo K.M., Chwastiak L. & Tek C. (2012) Contingency Man-
agement for the Treatment of Antipsychotic-Induced Weight Gain: A Randomized Con-
trolled Pilot Study. Obesity Facts 5(6), 919-927.  
Rege S. (2008) Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and 
Management. Australian & New Zealand Journal of Psychiatry 42(5), 369-381. 
multi-component review 
19 
19 of 19 
Riordan H., Murphy M. & Antonini P. (2011) Atypical Antipsychotics and metabolic syn-
drome in patients with schizophrenia: Risk factors, monitoring, and healthcare implications. 
American Health & Drug Benefits 4(5), 292–302.  
Shrivastava A. & Johnston M. (2010) Weight-gain in psychiatric treatment: Risks, implica-
tions, and strategies for prevention and management. Mens Sana Monographs 8(1), 53-
68.  
Usher K., Park T., Foster K. & Buettner P. (2012) A randomized controlled trial undertaken 
to test a nurse-led weight management and exercise intervention designed for people with 
serious mental illness who take second generation antipsychotics. Journal of Advanced 
Nursing 69(7), 1539-1548.  
Wu M.K., Wang C.K., Bai Y.M., Huang C.Y. & Lee SD (2007) Outcomes of obese, clozap-
ine-treated inpatients with schizophrenia placed on a six-month diet and physical activity 
program. Psychiatric Services 58(4), 544-550.  
Wu R., Zhao J., Jin H., Shao P., Fang M., Guo X., He Y., Liu Y., Chen J. & Li L. (2008) 
Lifestyle Intervention and Metformin for Treatment of Antipsychotic- Induced Weight Gain: 
A Randomized Controlled Trial. JAMA 299(2), 185-193.  
Zhang Z., Peluso M., Gross C., Viscoli C. & Kernan W. (2014) Adherence reporting in ran-
domized controlled trials. Clinical Trials 11(2), 195-204.  
 
 
  
Table 1: Summary of studies 
 
Author & year 
of publication 
Study 
location 
Study aim & main measures Number of participants, inclusion criteria, duration 
of study & control condition 
Lifestyle intervention 
components 
Method of data 
collection and analysis 
Main findings 
Wu et al. (2007) Taichung, 
Taiwan  
Study aim – To assess the efficacy of 
dietary control and exercise among 
obese inpatients with schizophrenia 
being treated with clozapine.  
Measures – BMI, body weight, body fat 
composition, waist-to-hip ratio (waist 
circumference and hip circumference) 
and fasting blood test (glucose, 
triglyceride, cholesterol, prolactin, 
cortisol and insulin).   
Number of participants – 53 (Intervention group – 28 
+ Control group – 25). 
Inclusion criteria - a diagnosis of schizophrenia, aged 
18 to 65 years old, taking at least 300 mg of clozapine 
orally per day for at least a year and having a BMI 
greater than 27 kg/m2. 
Duration of study – 6 months  
Control condition – Clozapine treatment as usual 
6 months of dietary 
intervention.  
6 months of exercise 
for an hour 3-times a 
week.  
Data collection – Data 
collected at baseline, 3 
months and 6 months. 
Data analysis – 
Statistical analyses 
using ANCOVA based 
on a general linear 
model. 
The intervention group 
participants experienced a 
statistically significant 
decrease in weight (kg). This 
additionally occurred with 
BMI (5.4% reduction), hip 
circumference and waist 
circumference (both 
reduced by 3.3 cm) during 
the trial and post-at 
intervention end.  
Wu et al. (2008) Hunan 
Province, 
China 
Study aim – To evaluate the effects of a 
lifestyle intervention and metformin 
both alone and in combination for 
antipsychotic-induced weight gain and 
abnormalities in insulin sensitivity.  
Measures – BMI, waist circumference 
and insulin levels.  
Number of participants – 64 (Lifestyle intervention 
group – 32 + Control group – 32). 
Inclusion criteria - aged 18 to 45, with a first psychotic 
episode of schizophrenia, had gained more than 10% 
of their predrug body weight within the first year of 
treatment with a targeted antipsychotic agent— 
clozapine, olanzapine, risperidone, or sulpiride,  had 
to have relatively stable improvement in psychotic 
symptoms, and be taking only 1 antipsychotic agent, 
whose dose had not changed by more than 25% over 
the past 3 months. 
Duration of study – 3 months 
Control condition – Placebo only 
3 months of 
psychoeducation 
about food and 
physical activity and 
exercise sessions 
Participants engaged 
in endurance exercise 
every day for 30 
minutes for the first 
week and then 
moderate exercise for 
30 minutes’ minimum 
daily.  
Data collection – Data 
collected at baseline, 1 
month, 2 months and 
3 months. 
Data analysis – 
Statistical analyses 
using ANCOVA to 
compare all 
continuous variables 
and x2 analysis was 
used for categorical 
variables.  
Intervention participants 
had a statistically significant 
decrease in all body weight 
parameters in comparison 
to the placebo group.  
Here, the placebo group has 
a significant increase in all 
body weight parameters. 
Table Click here to download Table DA paper Table 1 revised.docx 
  
Ratliff et al. 
(2012) 
New 
Haven, 
USA 
Study aim – To evaluate the feasibility 
of using contingency management (CM) 
to promote weight loss in individuals 
with serious mental illness over 2 
months. 
Measures – BMI, waist circumference, 
weight, plasma glucose levels, plasma 
insulin levels, glycosylated haemoglobin.    
Number of participants – 30 (Lifestyle intervention 
group with CM via attendance – 10 + Lifestyle 
intervention group with CM via weight loss - 10 + 
Waitlist control/ CM for behaviour group – 10). 
Inclusion criteria - aged 18 to 70 years with SMI who 
were on a stable dose of antipsychotics for at least 1 
month and self-reported weight gain 6 5% over the 
past 5 years  
Duration of study – 2 months 
Control condition – Waiting list 
Lifestyle intervention 
group with CM via 
attendance – The 
lifestyle intervention 
consisted of weekly, 
hour-long group 
sessions to provide 
knowledge on diet and 
physical activity. 
Participants received 
either 1) attendance, 
2) weight loss, 3) 
behaviour change. 
Data collection – 
Weight was measured 
weekly after baseline. 
All other outcomes 
were measured at 
baseline and at the 2 
months. 
Data analysis – 
Statistical analyses 
using ANCOVA and 
Spearman’s 
correlation coefficient. 
Participants in the CM 
attendance and CM weight 
group lost a mean of 1.16 kg 
and 1.23 kg receptively, 
while subjects in the CON 
gained a mean of 0.68 kg. 
Participants in the CM 
behaviour group lost a 
mean of 2.54kg, which was 
a statistically significant in 
comparison to the control 
group. 
Usher et al. 
(2012) 
 Study aim – To assess the effectiveness 
of a nurse-led intervention on weight 
gain in people with serious mental 
illness prescribed and taking second 
generation antipsychotic medication. 
Measures – BMI (Height + Weight), 
medication compliance. 
Sampling strategy – Purposive sampling through 
advertisement in outpatients. 
Number of participants – 101 (Lifestyle intervention 
group – 51 + Control group – 50). 
Duration of study – 3 months 
Control condition – Education booklet 
One-hour group 
sessions every week 
for three months. The 
group session included 
education on different 
healthy lifestyle topics. 
After the group there 
was a 30 minutes of 
physical activity.   
Data collection – Data 
collected by the 
researchers at 
baseline and 3 
months. 
Data analysis – 
Statistical analyses 
using Chi-squared 
texts, Fisher’s exact 
tests, unpaired t-tests 
and non-parametric 
Mann-Whitney 
Wilcoxon U-tests.  
Results were not statistically 
significant. The intervention 
group had a decrease in 
weight at intervention end 
of -0.74 kg. However, the 
control group also had a 
decrease in weight, this was 
-0.17 kg at intervention end.  
  
Attux et al. 
(2013) 
Sao Paulo, 
Brazil 
Study aim – To test the efficacy of a 12-
week group behavioural and 
psychoeducation interventions on 
weight gain management. 
Measures – BMI, body weight, waist 
circumference, systolic BP, diastolic BP 
and fasting blood test (glucose, 
triglyceride, cholesterol and insulin 
levels).   
Number of participants – 160 (Intervention group – 
81 + Control group – 79). 
Inclusion criteria- aged between 18 and 65, using any 
antipsychotic in the past three months, presenting a 
diagnosis on the schizophrenia spectrum, motivated 
to lose weight or have showed some concern about 
weight gain. 
Duration of study – 6 months  
Control condition – Treatment as usual  
3 months of one-
hourly weekly sessions 
to discuss topics such 
as lifestyle and diet 
and behaviour 
techniques i.e. diaries.  
Data collection – Data 
collected at baseline, 3 
months and 6 months. 
Data analysis – 
Statistical analyses 
using ANOVA for 
comparison of the 
groups and two sided 
t-tests and chi-square 
tests to analyse the 
differences between 
groups at baseline and 
follow up. 
At the intervention end, 
intervention group 
participants had a weight 
loss of 0.48 kg while the 
control group experienced 
an increase of 0.48 kg. This 
was not statistically 
significant at 3 months’ post 
intervention, the 
intervention group lost a 
statistical significant weight 
loss of -1.15 kg. 
Green et al. 
(2014) 
Oregon, 
USA 
Study aim – To test the efficacy of a 12-
week weight reduction intervention for 
overweight individuals taking 
antipsychotic medications. 
Measures – Height, weight, blood 
pressure.  
Number of participants – 36 (Intervention group – 18 
+ Control group – 18). 
Inclusion criteria - BMI of 25–44.9) aged over 18 years 
who had been taking at least one antipsychotic 
medication at any consistent dose for a minimum of 
30 days at the time they were identified.  
Duration of study – 3 months  
Control condition –Treatment as usual 
3-month intervention 
composed of a 
moderate calorie 
restriction, increase in 
healthier food, 
increase in physical 
exercise and daily use 
of a food diary. 
Data collection – Data 
collected by blinded 
staff at baseline, and a 
week post-treatment. 
Data analysis – 
Statistical analyses 
using ANOVA. 
Here there was a 
statistically significant 
decrease in the weight of 
intervention from 213.3 to 
206.6 pounds. Control 
group participants had a 
relatively unchanged 
weight. BMI results 
mirrored this.  
Masa-Font et 
al. (2015) 
Barcelona, 
Spain 
Study aim – To evaluate the 
effectiveness of a physical activity and 
diet to change the amount of physical 
activity, BMI and waist circumference in 
patients with severe mental illness. 
Measures – Level of physical activity, 
BMI, waist circumference, cholesterol, 
triglycerides, glucose, metabolic 
equivalent units (METS) dietary habits 
and quality of life.  
Number of participants – 332 (Intervention group – 
169 + Control group – 163). 
Inclusion criteria - diagnosed with a schizophrenic, 
schizoaffective or bipolar disorder, undergoing 
treatment with an antipsychotic drug for at least 3 
months prior to enrollment, with low Physical Activity, 
BMI values equal to or greater than 25 
Duration of study – 3 months  
Control condition – 
Treatment as usual 
Twice-weekly physical 
activity interventions 
(between 40-60 
minutes) and twice-
weekly diet education 
sessions (20 minutes 
each). 
Data collection – Data 
collected by blinded 
staff at baseline and at 
3 months. 
Data analysis – 
Statistical analyses 
using ANOVA. 
At 3 months, the BMI 
decreased significantly 
more in the control group, 
by 0.26 kg/ m 2 than in the 
IG. There were no 
significant differences in the 
waist circumference. 
  
Green et al. 
(2015) 
Oregon, 
USA 
Study aim – To assess where a tailored 
lifestyle intervention for individuals with 
serious mental illness produces weight 
loss and lowered diabetic risk. 
Measures – Blood pressure, BMI (height 
and weight), and fasting blood sample 
(insulin, plasma glucose, triglycerides 
and cholesterol).  
Number of participants – 200 (Intervention group – 
104 + Control group – 96). 
Inclusion criteria  -adults (age $18) taking 
antipsychotic agents for over 30 days prior to 
enrollment and with a BMI over 27.  
 
Duration of study – 12 months (Initial intervention – 6 
months + Maintenance intervention – 6 months).   
Control condition –  
Treatment as usual  
Initial intervention –  
6 months of weekly 2-
hour group meetings 
to support self-
management and diet 
changes (DASH diet) 
with 20 minutes of 
physical activity.  
Maintenance 
intervention –  
6 months of group 
sessions focusing on 
motivation 
enhancement. 
Additionally, monthly 
individual telephone 
sessions to support 
problem-solving. 
Data collection – 
Blinded staff collected 
data at baseline, 6 
months and 12 
months.  
Data analysis – 
Statistical analyses 
using one way 
ANCOVA and multiple 
logistic regression. 
Intervention participants 
lost 4.4 kg more than 
control participants from 
baseline to 6 months.  Here 
control groups participants 
experienced an increase in 
weight (kg).  
Intervention participants 
lost 2.6 kg more than 
control participants from 
baseline to 12 months 
(intervention end). 
 
  
Table 2: Risk of Bias 
Risk of bias 
domain 
Wu et al. (2007) Wu et al. (2008) Ratliff et al. 
(2012) 
Usher et al. 
(2012) 
Attux et al. 
(2013) 
Green et al. 
(2014) 
Masa-Font et al. 
(2015) 
Green et al. 
(2015) 
Random 
sequence 
allocation 
(selection bias) 
? + + ? + + + + 
Allocation 
concealment 
(selection bias) 
? + ? + ? + + + 
Blinding of 
participants 
(performance 
bias) 
- - - - - - - - 
Blinding of 
outcome 
assessment 
(detection bias) 
- + ? - - + + + 
Incomplete 
outcome data 
(attrition bias) 
+ ? ? ? ? + ? + 
Selective 
reporting 
(reporting bias) 
+ + - + + - + ? 
Lack of intent-to-
treat analysis - + + - + + + + 
 
Table Click here to download Table Table 2 risk of bias.docx 
  
 
Key: + = Low risk of bias? = Unclear risk of bias, - = High risk of bias. 
Figure 1 Selection process flow chart 
Records identified through 
database searching  
(n = 1,167)
Additional records identified 
through hand searching  
(n = 0)
Records screened by date (n = 1,167)
Records screened by 
title 
Records excluded after 
date screen (n = 769)
Records screened by 
abstract 
(n = 142)
Records excluded after 
title screen (n = 72)
Full-text articles 
assessed for eligibility (n 
= 70)
Studies included in the 
review  
(n = 8)
Records excluded after 
abstract screen (n = 46)
Records screened for 
duplicates (n = 23)
Records excluded after 
full-text screened for 
eligibility (n = 15)
Figure 1 Click here to download Figure (i.e. diagram, illustration, photo)
Figure 1 Selection process flow chart.pdf
Figure 2: Weight change in intervention and control groups from baseline to end (kg) 
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Figure 3 BMI change in intervention and control groups from baseline to end (kg/m2) 
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Figure 4: Waist circumference change in intervention and control groups from baseline to end (cm) 
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